Suggested Remit: To appraise the clinical and cost effectiveness of budesonide within its marketing authorisation for treating active eosinophilic oesophagitis.
Status In progress
Process STA 2018
ID number 1202

Provisional Schedule

Committee meeting: 1 16 April 2020
Expected publication 08 July 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors Dr Falk
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups EOS NETWORK
Professional groups British Society for Allergy and Clinical Immunology
  Royal College of Physicians


General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  National Pharmacy Association
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
25 July 2019 The timelines for this appraisal have been revised. NICE have agreed to allow the company additional time to update their submission in response to the Evidence Review Group's clarification questions. The first committee meeting is now expected to take place on Thursday 16 April 2020.
19 December 2018 In progress, In progress
19 December 2018 Invitation to participate
07 September 2018 (14:00) Scoping workshop (London)
25 July 2018 - 22 August 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance